1. No category

Mixed Dyslipidemia Market Share, Size, Symptoms, Analysis,
Overview and Pipeline Review, H1 2016
Summary
Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H1 2016', provides an overview of the Mixed
Dyslipidemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia,
complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases. Additionally, the report provides
an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and
discontinued projects.
To Get Full Report Click Here @ http://www.radiantinsights.com/research/mixed-dyslipidemia-pipeline-reviewh1-2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia
- The report reviews pipeline therapeutics for Mixed Dyslipidemia by companies and universities/research
institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description,
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mixed Dyslipidemia therapeutics and enlists all their major and minor
projects
- The report assesses Mixed Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mixed Dyslipidemia
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus
of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove
them from pipeline
Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/mixed-dyslipidemia-pipelinereview-h1-2016/request-sample
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mixed Dyslipidemia Overview 6
Therapeutics Development 7
Pipeline Products for Mixed Dyslipidemia - Overview 7
Mixed Dyslipidemia - Therapeutics under Development by Companies 8
Mixed Dyslipidemia - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Mixed Dyslipidemia - Products under Development by Companies 12
Mixed Dyslipidemia - Companies Involved in Therapeutics Development 13
Amgen Inc. 13
CymaBay Therapeutics, Inc. 14
Hanmi Pharmaceuticals, Co. Ltd. 15
Matinas BioPharma Holdings, Inc. 16
Pfizer Inc. 17
Thetis Pharmaceuticals LLC 18
Mixed Dyslipidemia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
bococizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
evolocumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
To Get Full Report Click Here @ http://www.radiantinsights.com/research/mixed-dyslipidemia-pipeline-reviewh1-2016
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure market research reports, helping them
in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries
and a host of micro markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research
solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: http://www.radiantinsights.com/
Email: [email protected]
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com